We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Health Benefits of Conjugated Linoleic Acid (CLA) for Asthma & Allergy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00876356
Recruitment Status : Completed
First Posted : April 6, 2009
Last Update Posted : April 6, 2009
Information provided by:

Study Description
Brief Summary:
Conjugated linoleic acids (CLA) are naturally occurring free fatty acids derived from the tissues and milk of ruminant animals such as cows. CLA has multiple biological properties including regulation of metabolism and immune processes, including tissue inflammation. Asthma symptoms are caused by irritation and inflammation of the airways. Our hypothesis was that CLA may reduce airway inflammation in asthma and thus reduce asthma symptoms. The aim of this pilot study was to investigate the efficacy and safety of CLA as a dietary supplement in mild asthma. Subjects will be assigned to take CLA dietary supplements or placebo (olive oil) for 12 weeks in addition to their usual asthma treatment. They will be monitored for asthma symptoms, side effects, lung function and blood markers of inflammation.

Condition or disease Intervention/treatment
Asthma Dietary Supplement: Conjugated Linoleic Acid (CLA) Dietary Supplement: Olive oil

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Conjugated Linoleic Acid (CLA) as Adjunctive Therapy in Mild Asthmatics: A Pilot Study.
Study Start Date : May 2002
Primary Completion Date : May 2002
Study Completion Date : September 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1
Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
Dietary Supplement: Conjugated Linoleic Acid (CLA)
CLA 4.5g/day in three divided doses p.o. for 12 weeks
Placebo Comparator: 2
Olive oil 4.5g/day x 12 weeks.
Dietary Supplement: Olive oil
Olive oil 4.5g/day x 12 weeks

Outcome Measures

Primary Outcome Measures :
  1. PC20 - methacholine sensitivity [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Quality of life (QoL), body mass index (BMI), systemic cytokine levels, and adverse events. [ Time Frame: 12 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Mild asthma - FEV1 > 70% predicted Positive methacholine challenge

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00876356

Canada, British Columbia
St. Paul's Hospital
Vancouver, British Columbia, Canada, V6Z 1Y6
Sponsors and Collaborators
University of British Columbia
Canadian Institutes of Health Research (CIHR)
Canadian Lung Association/British Columbia Lung Association
Natural Inc./Cognis GmbH (Dusseldorf, Germany)
Principal Investigator: Delbert Dorscheid, MD, Ph.D University of British Columbia
Study Director: Ruth MacRedmond, MD, FRCPC University of British Columbia
More Information

Responsible Party: Dr. Delbert R. Dorscheid, University of British Columbia
ClinicalTrials.gov Identifier: NCT00876356     History of Changes
Other Study ID Numbers: P01-0180
First Posted: April 6, 2009    Key Record Dates
Last Update Posted: April 6, 2009
Last Verified: April 2009

Keywords provided by University of British Columbia:
Conjugated Linoleic Acid (CLA)
dietary supplement

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases